FDMT logo

FDMT4D Molecular Therapeutics Inc

$8.67
$0.55
(5.96%)
Today
Closed $8.67
$0.00
(0.00%)
After Hours
Updated: 07:14 PM EDT
EarningsAug 10
Mkt Cap$481.99M
Vol766,910.00
News
all
press releases
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, Marketbeat.com...
MarketBeat
News Placeholder
electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?
electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after...
MarketBeat
News Placeholder
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group
Jefferies Financial Group reiterated a "buy" rating and issued a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday...
MarketBeat
News Placeholder
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings...
MarketBeat
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase - Here's What Happened...
MarketBeat
News Placeholder
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's What Happened...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.